Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 203-212

  Ferreira, Carlos G ^a   Tolis, Christos ^a   Span, Simone W ^a   Peters, Godefridus J ^a   Van Lopik, Thea ^b   Kummer, Alain J ^a   Pinedo, Herbert M ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CISPLATIN; FAS ANTIGEN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CASPASE 8; CASPASE 9; CASPASES; CISPLATIN; DEOXYCYTIDINE; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENES, P53; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; PACLITAXEL; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TOPOTECAN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033971809     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994.
2. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
3. Los, M., Herr, I., Friesen, C., Fulda, S., Schulze-Osthoff, K., and Debatin, K. M. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 90: 3118-3129, 1997.
4. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
5. Micheau, O., Solary, E., Hammann, A., Martin, F., and Dimanche-Boitrel, M. T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst., 89: 783-789, 1997.
6. Smith, C. A., Farrah, T., and Goodwin, R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76: 959-962, 1994.
7. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T., and Nagata, S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol., 6: 1567-1574, 1994.
8. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
9. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J., 14: 1129-1135, 1995.
10. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
11. Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O'Rourke, K., Kischkel, F. C., Hellbardt, S., Krammer, P. H., Peter, M. E., and Dixit, V. M. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem., 271: 4961-4965, 1996.
12. Zhang, J., and Winoto, A. A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol. Cell. Biol., 16: 2756-2763, 1996.
13. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.
14. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
15. Baker, S. J., and Reddy, E. P. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene, 12: 1-9, 1996.
16. Debatin, K. M. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J. Natl. Cancer Inst., 89: 750-751, 1997.
17. Houghton, J. A., Harwood, F. G., and Tillman, D. M. Thymineless death in colon carcinoma cells is mediated via Fas signaling. Proc. Natl. Acad. Sci. USA, 94: 8144-8149, 1997.
18. Tillman, D. M., Petak, I., and Houghton, J. A. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res., 5: 425-430, 1999.
19. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug- induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
20. Friesen, C., Fulda, S., and Debatin, K. M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia (Baltimore), 11: 1833-1841, 1997.
21. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
22. Fulda, S., Los, M., Friesen, C., and Debatin, K. M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer, 76: 105-114, 1998.
23. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997.
24. Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., and Kaufmann, S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90: 935-943, 1997.
25. Ferrari, D., Stepczynska, A., Los, M., Wesselborg, S., and Schulze-Osthoff. K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J. Exp. Med., 188: 979-984, 1998.
26. Gamen, S., Anel, A., Lasierra, P., Alava, M. A., Martinez-Lorenzo, M. J., Pineiro, A., and Naval, J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett., 417: 360-364, 1997.
27. Kataoka, T., Schroter, M., Hahne, M., Schneider, P., Irmler, M., Thome, M., Froelich, C. J., and Tschopp, J. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J. Immunol., 161: 3936-3942, 1998.
28. McGahon, A. J., Costa, P. A., Daly, L., and Cotter, T. G. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br. J. Haematol., 101: 539-547, 1998.
29. Villunger, A., Egle, A., Kos, M., Hartmann, B. L., Geley, S., Kofler, R., and Greil, R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res., 57: 3331-3334, 1997.
30. Tolis, C., Peters, G. J., Ferreira, C. G., Pinedo, H. M., and Giaccone, G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur. J. Cancer, 35: 796-807, 1999.
31. van Lopik, T., Bijl, M., Hart, M., Boeije, L., Gesner, T., Creasy, A. A., Kallenberg, C. G., Aarden, L. A., and Smeenk, R. J. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J. Rheumatol., 26: 60-67, 1999.
32. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
33. Koopman, G., Reutelingsperger, C. P., Kuijten, G. A., Keehnen, R. M., Pals, S. T., and van Oers, M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84: 1415-1420, 1994.
34. Boyle, J. O., Hakim, J., Koch, W., van der Riet, P., Hruban, R. H., Roa, R. A., Correo, R., Eby, Y. J., Ruppert, J. M., and Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 53: 4477-4480, 1993.
35. Brennan, J. A., Mao, L., Hruban, R. H., Boyle, J. O., Eby, Y. J., Koch, W. M., Goodman, S. N., and Sidransky, D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck [see comments]. N. Engl. J. Med., 332: 429-435, 1995.
36. Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., and Frost, P. Identification of p53 gene mutations in bladder cancers and urine samples. Science (Washington DC), 252: 706-709, 1991.
37. Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., and Ohgaki, H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res., 58: 2057-2062, 1998.
38. Leithauser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K. M., Krammer, P. H., and Moller, P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Investig., 69: 415-429, 1993.
39. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. Human lung carcinomas express Fas ligand. Cancer Res., 57: 1007-1012, 1997.
40. Pitti, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kishkel, F. C., Dowd, P., Huang A., Donahue C. J., Sherwood, S. W., Baldwin, D. T., Godowski, P. J., Wood, W. I., Gurney, A. L., Hillan, K. J., Cohen, R. L., Goddard, A. D., Botstein, D., and Ashkenazi, A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (Lond.), 396: 699-703, 1998.
41. Irmler, M., Thome, M., Hahne, M., Schneider P., Hofmann, K., Steiner, V., Bodmer, J. L., Schröter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. Inhibition of death-receptor signals by cellular FLIP. Nature (Lond.), 388: 190-195, 1997.
42. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., and Kruzel, E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.
43. Versantvoort, C. H., Withoff, S., Broxterman, H. J., Kuiper, C. M., Scheper, R. J., Mulder, N. H., and de Vries, E. G. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing Adriamycin resistance. Int. J. Cancer, 61: 375-380, 1995.
44. Landowski, T. H., Gleason-Guzman, M. C., and Dalton, W. S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89: 1854-1861, 1997.
45. Yen, W. C., Pompa, J. L., McCurrach, M. E., Shu, H. B., Elia, A. J., Shahinian, A., Ng, M., Wakeham, A., Khoo, W., Mitchell K., El-Deiry, W. S., Lowe, S. W., Goeddel, D. V., and Mak, T. W. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (Washington DC), 279: 1954-1958, 1998.
46. Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez, G., Krammer, P. H., Peter, M. E., and Debatin, K. M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 57: 4956-4964, 1997.
47. Slee, E. A., Harte, M. T., Kluck, R. M., Wolf, B. B., Casiano, C. A., Newmeyer, D. D., Wang, H. G., Reed, J. C., Nicholson, D. W., Alnemri, E. S., Green, D. R., and Martin, S. J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol., 144: 281-292, 1999.
48. Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.
49. Fulda, S., Susin, S. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998.
50. Boesen-de Cock, J. G. R., de Vries, E., Williams, G. T., and Borst, J. The anticancer drug etoposide can induce caspase-8 processing and apoptosis in the absence of CD95 receptor-ligand interaction. Apoptosis, 3: 17-25, 1998.
51. Hu, Y., Benedict, M. A., Dayang, W., Inihara, N., and Nunez, G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA, 95: 4386-4391, 1998.
52. Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K. M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
53. Roth, W., Wagenknecht, B., Grimmel, C., Dichgans, J., and Weller, M. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br. J. Cancer, 77: 404-411, 1998.
54. Scaffidi, C., Medema, J. P., Krammer, P. H., and Peter, M. E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem., 43: 26953-26958, 1997.